Autolus Presents Updated CARLYSLE Study Results at ACR Convergence 2025

Autolus Therapeutics announces the online publication of an abstract for the American College of Rheumatology Convergence 2025. The abstract, titled "Obecabtagene autoleucel (obe-cel) in severe refractory systemic lupus erythematosus," presents preliminary results from the Phase I CARLYSLE study. Autolus will have a poster presentation on October 28, 2025, including updated follow-up from the study.

Autolus Therapeutics has announced the online publication of an abstract for the American College of Rheumatology Convergence 2025. The abstract, titled "Obecabtagene autoleucel (obe-cel) in severe refractory systemic lupus erythematosus," presents preliminary results from the Phase I CARLYSLE study. The company will have a poster presentation on October 28, 2025, including updated follow-up from the study.

The abstract provides insights into the safety and efficacy of obecabtagene autoleucel (obe-cel), a chimeric antigen receptor (CAR) T-cell therapy, in patients with severe refractory systemic lupus erythematosus (SLE). This study is significant as it marks one of the first attempts to apply CAR-T cell therapy to treat SLE, a chronic autoimmune disease with limited treatment options.

The Phase I CARLYSLE study enrolled 15 patients with severe refractory SLE, and the preliminary results suggest that obe-cel demonstrates promising safety and efficacy profiles. The study aims to evaluate the safety and feasibility of CAR-T cell therapy in SLE patients and assess the potential therapeutic benefits. The abstract highlights the preliminary data on the treatment's impact on disease activity and patient outcomes.

Autolus Therapeutics' poster presentation at the American College of Rheumatology Convergence 2025 will provide further details on the study's progress and the updated follow-up data. The company's leadership in developing innovative cell therapies positions it as a leader in the field of autoimmune disease treatment.

As investors and financial professionals, it is essential to monitor the progress of this study and the broader potential of CAR-T cell therapies in treating autoimmune diseases. The success of the CARLYSLE study could open new avenues for the treatment of SLE and other autoimmune disorders, potentially expanding Autolus Therapeutics' market reach and value proposition.